Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07037758 · ClinicalTrials.gov registry record · Phase 1
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
A Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 380
- Enrollment target
- 17
- Study locations
NCT07037758: Recruiting Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Amgen.
NCT07037758 is a Phase 1 study of Extensive-stage Small-cell Lung Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 380 participants, above the 160-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (138% higher). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07037758, a Phase 1 study of Extensive-stage Small-cell Lung Cancer, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 380 participants
- Enrollment target
- 17
- Study locations
Study Summary
The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.
Primary Outcome
Clinically significant changes in vital signs and clinical laboratory tests will be reported as adverse events.
Conditions Studied
Interventions
- DRUG Tarlatamab
- DRUG AB248
Study Locations (17)
Other
- Chungbuk National University Hospital - Cheongju Chungbuk
- Seoul National University Bundang Hospital - Seongnam-si, Gyeonggi-do
- Severance Hospital Yonsei University Health System - Seoul
- Adana Sehir Egitim ve Arastirma Hastanesi - Adana
- Hacettepe Universitesi Tip Fakultesi Hastanesi - Ankara
- Ankara Bilkent Sehir Hastanesi - Ankara
Pennsylvania
- Sidney Kimmel Cancer Center - Philadelphia
- Allegheny General Hospital - Pittsburgh
California
- University of Southern California, Norris Comprehensive Cancer Center - Los Angeles
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Emory University - Atlanta
Kentucky
- Norton Cancer Institute - Downtown - Louisville
Massachusetts
- Dana-Farber Cancer Institute - Boston
Missouri
- Siteman Cancer Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2031-01-18 |
| Phase | Phase 1 |
What NCT07037758 shows while recruiting
NCT07037758 is an interventional study that assigns participants to a tested intervention. The registered 380 participants enrollment target is mid-sized for trials with a published cap, above the 160-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (138% higher).
The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Tarlatamab is the first listed.
NCT07037758 lists 17 locations in 11 states (Other, Pennsylvania, California).
Frequently Asked Questions
What is clinical trial NCT07037758 about?
NCT07037758 is a clinical study titled "A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)". The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB...
What is the current status of trial NCT07037758?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 380 participants. The study started on 2025-09-16. Estimated completion is 2031-01-18.
What conditions does trial NCT07037758 study?
This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.
What interventions are being tested in trial NCT07037758?
The interventions under investigation include: Tarlatamab (DRUG), AB248 (DRUG).
Who is sponsoring clinical trial NCT07037758?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07037758 being conducted?
This trial has 17 study locations across California, Florida, Georgia, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive-stage Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07037758's enrollment target sits among peer trials
380 4th of 25 higher than 22 of 25 other Extensive-stage Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Extensive-stage Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
RECRUITING · Phase 1
-
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
RECRUITING · Phase 1
-
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
RECRUITING · Phase 1
-
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
ACTIVE NOT RECRUITING · Phase 1
-
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI